Sellas Life Sciences Group
Nasdaq SLS · New York, NY
Works in Cardiovascular · Dermatology · Genetic & rare · GI & liver · Hematology · Immunology · Metabolic & endocrine · Oncology · Renal & urogenital · Respiratory · Women's health
Sellas Life Sciences Group is a clinical trial sponsor based in New York, NY, listed as Nasdaq SLS. It has 2 active clinical trials with 287 planned participants, across 11 therapeutic areas. Since 2021 it has completed 4 trials and stopped 0 early.
Trial track record · since 2021
Financials · Nasdaq SLS
Fundraising
Pipeline · 2 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about Sellas Life Sciences Group
Sellas Life Sciences Group is lead sponsor of 2 active clinical trials on ClinicalTrials.gov, with 287 planned participants, in Cardiovascular, Dermatology, Genetic & rare, GI & liver and other areas. Since 2021 it has completed 4 trials and stopped 0 early.
Sellas Life Sciences Group is based in New York, NY and is listed as Nasdaq SLS. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Sellas Life Sciences Group; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-09-03.
Approve Suite is not affiliated with Sellas Life Sciences Group.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.